Method for stimulating T lymphocytes with IL-2

Patent metadata

Field	Value
Publication number	US-9669071-B2
Application number	US-201214004211-A
Country	US
Kind code	B2
Filing date	Mar 9, 2012
Priority date	Mar 11, 2011
Publication date	Jun 6, 2017
Grant date	Jun 6, 2017

Abstract

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.

First claim

The invention claimed is:

1. A method for stimulating regulatory T lymphocytes (Tregs) in a human subject suffering from type T diabetes, the method comprising subcutaneously administering interleukin-2 (IL-2) to the human subject at a dose of between 0.1 and 3.5 MIU/day in a first course of treatment, wherein the first course of treatment is followed by a maintenance dose, wherein the first course of treatment consists of an administration of IL-2 once per day for at least 3 consecutive days, and wherein the maintenance dose is given to the subject once a week or once or twice a month.

2. The method of claim 1 , wherein the human subject is administered with IL-2 at a dose of 3 MIU/day in the first course of treatment.

3. The method of claim 1 , wherein the human subject is administered with IL-2 at a dose of less than 2 MIU/day in the first course of treatment.

4. The method of claim 1 , wherein the subject is administered with IL-2 at a dose of between 0.25 and 3.5 MIU/day in the first course of treatment.

5. The method of claim 1 , wherein the first course of treatment consists of an administration of IL-2 once per day for 3 to 7 days.

6. The method of claim 1 , wherein the maintenance dose starts 1 to 4 weeks after the last dose of the first course of treatment.

7. The method of claim 1 , wherein the subject is administered with IL-2 at a dose of 1.5 MIU/day in the first course of treatment.

8. The method of claim 1 , wherein the subject is a child.

9. The method of claim 1 , wherein the maintenance dose is given to the subject once a week.

10. The method of claim 1 , wherein the maintenance dose is given to the subject once or twice a month.

11. A method for stimulating regulatory T lymphocytes (Tregs) in a human subject suffering from type I diabetes, the method comprising subcutaneously administering interleukin-2 (IL-2) to the human subject at a dose of between 0.05 and 2 MIU/m 2 /day in a first course of treatment, wherein the first course of treatment is followed by a maintenance dose, wherein the first course of treatment consists of an administration of IL-2 once per day for at least 3 consecutive days, and wherein the maintenance dose is given to the subject once a week or once or twice a month.

12. The method of claim 11 , wherein the subject is administered with IL-2 at a dose of between 0.2 and 1 MIU/m 2 /day in the first course of treatment.

13. The method of claim 11 , wherein the human subject is administered with IL-2 at a dose of 0.2 to 0.6 MIU/m 2 /day in the first course of treatment.

14. The method of claim 11 , wherein the subject is a child.

15. The method of claim 11 , wherein the first course of treatment consists of an administration of IL-2 once per day for 3 to 7 days.

16. The method of claim 15 , wherein the maintenance dose starts 1 to 4 weeks after the last dose of the first course of treatment.

17. The method of claim 11 , wherein the maintenance dose is given to the subject once a week.

18. The method of claim 11 , wherein the maintenance dose is given to the subject once or twice a month.

Assignees

• Klatzmann David
• Saadoun David
• Cacoub Patrice
• Rosenzwajg Michèle
• Piaggio Eliane
• Bensimon Gilbert
• Claude Bernard
• Inserm (Institut Nat De La Santé Et De La Rech Médicale)
• Assist Publique—Hopitaux De Paris
• Univ Pierre Et Marie Curie Paris 6

Inventors

• Klatzmann David
• Saadoun David
• Cacoub Patrice
• Rosenzwajg Michèle
• Piaggio Eliane
• Bensimon Gilbert
• Bernard Claude

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title